The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | ARTEMIS-PC: personalized panel for circulating tumor DNA in pancreatic cancer
Edward D. Esplin, MD, PhD, Invitae, San Francisco, CA discusses the urgent need for innovative diagnostic and therapeutic approaches in pancreatic cancer (PC). Current challenges include the low sensitivity of circulating tumor DNA (ctDNA) assays in PC due to its high stromal and low cellular features. The Invitae Personalized Cancer Monitoring™ test, a novel and highly sensitive tumor-informed minimal residual disease (MRD) detection assay, is introduced. The ARTEMIS-PC study (NCT06043921), a prospective observational trial in Japan, aims to assess the clinical utility of this assay in 150 patients with resectable and unresectable PC. Primary and secondary endpoints include the success rate of creating personalized panels, concordance of KRAS mutations, and ctDNA positivity rates at various stages. The study commenced enrollment in December 2022. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
